News for OliX Pharmaceuticals,Inc (226950.KQ)

The global Antisense and RNAi Therapeutics Market size and share is currently valued at USD 4.34 billion in 2023. It is anticipated to generate an...

/PRNewswire/ -- The

/PRNewswire/ -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company has identified...

SUWON, Republic of Korea., Jan. 03, 2022 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today

SUWON, Republic of Korea, Oct. 21, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today

Companies to focus on cardiovascular, metabolic, and other indications OliX will receive initial upfront payment of $6.5 million with up to $450 million

SUWON, Republic of Korea, Aug. 12, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today

(Bloomberg) -- The latest surge in Covid-19 cases is widening one of the biggest inequities of the pandemic era: The gap between nations that have messenger RNA vaccines and those that don’t.

SUWON, Republic of Korea, June 14, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today